Home » Stocks » ARVN

Arvinas, Inc. (ARVN)

Stock Price: $107.87 USD 4.02 (3.87%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $105.25 -2.62 (-2.43%) Jul 29, 4:57 PM
Market Cap 4.97B
Revenue (ttm) 21.10M
Net Income (ttm) -138.56M
Shares Out 49.12M
EPS (ttm) -3.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $107.87
Previous Close $103.85
Change ($) 4.02
Change (%) 3.87%
Day's Open 104.03
Day's Range 102.04 - 108.47
Day's Volume 652,019
52-Week Range 19.68 - 108.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 days ago - Zacks Investment Research

Arvinas, Inc. (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 days ago - Zacks Investment Research

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the...

3 days ago - Zacks Investment Research

Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas.

Other stocks mentioned: PFE
6 days ago - Zacks Investment Research

The smaller biopharma outfit just inked an encouraging deal with an industry powerhouse.

1 week ago - The Motley Fool

Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) have collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein deg...

Other stocks mentioned: PFE
1 week ago - Benzinga

– Collaboration combines Arvinas' investigational estrogen receptor-targeting breast cancer therapy with Pfizer's deep experience in breast oncology therapeutics –

1 week ago - GlobeNewsWire

NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined...

1 month ago - GlobeNewsWire

NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announc...

2 months ago - GlobeNewsWire

The Dow Jones climbed 220 points, the S&P 500 gained 0.8%, and the Nasdaq recovered another 1%. If you're looking for a way to play this market, the deep learning algorithms at Q.ai have crunched the da...

2 months ago - Forbes

– Company to lease approximately 160,000-square-feet to allow continued growth and expansion of operations – – Company to lease approximately 160,000-square-feet to allow continued growth and expansion ...

2 months ago - GlobeNewsWire

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -7.69% and 41.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today rep...

2 months ago - GlobeNewsWire

The markets look like they may have a losing week ahead, despite today's gains. If you're looking for opportunities, the deep learning algorithms at Q.ai have crunched the data to give today's top shorts.

Other stocks mentioned: BE, LPSN, MPAA, PLYA
3 months ago - Forbes

The Dow Jones rose over 200 points, the S&P 500 gained 0.7%, and the Nasdaq advanced 1% with excitement over lower-than-expected jobless claims and higher-than-expected retail sales. Make the most of th...

Other stocks mentioned: GE, LAUR, SYY, VTR
3 months ago - Forbes

Earlier this year, we talked about why Arvinas stock (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, is vulnerable to downside risk.

3 months ago - Forbes

NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...

3 months ago - GlobeNewsWire

Investors saw some downwards pressure on the indices to kick off Monday. But Q.ai's deep learning algorithms have crunched the numbers to bring you today's top short plays.

Other stocks mentioned: CVNA, NSTG, PLUG, RDFN
4 months ago - Forbes

Bank shares are leading the way in what looks to be a green day. In the meantime, Q.ai's deep learning algorithms have crunched the numbers to bring you today's top shorts.

Other stocks mentioned: PAR, ZVO
4 months ago - Forbes

Today marks the one-year anniversary since the start of the bull market. Make the most of it with today's top short plays from Q.ai's deep learning algorithms.

Other stocks mentioned: ALGT, CVNA, NCMI
4 months ago - Forbes

NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...

4 months ago - GlobeNewsWire

Bond yields are rising again, crushing tech stocks. But the deep learning algorithms at Q.ai have crunched the data to give you a set of Top Shorts for today.

Other stocks mentioned: CDLX, RDFN, SABR, WKHS
4 months ago - Forbes

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -26.92% and -70.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of Arvinas (NASDAQ:ARVN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share decreased 76.79% year over year to ($0.99), which missed the estimate of (...

4 months ago - Benzinga

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5 months ago - Zacks Investment Research

NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announ...

5 months ago - GlobeNewsWire

Arvinas is a leader in protein degrader technology. They have shown first outstanding results in phase 1 trials in breast and prostate cancer.

6 months ago - Seeking Alpha

NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PRO...

7 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: FL, GME, NTAP, BCAB, COUP, EOSE, GWRE ...
7 months ago - Benzinga

NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PRO...

7 months ago - GlobeNewsWire

Arvinas (ARVN) announces promising interim data on its two clinical stage pipeline candidates, ARV-471 and ARV-110, for treating breast cancer and prostate cancer, respectively.

7 months ago - Zacks Investment Research

NEW HAVEN, Conn., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PRO...

7 months ago - GlobeNewsWire

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific upd...

Other stocks mentioned: ANPC, ARPO, SYBX, VERU
7 months ago - Benzinga

Arvinas (ARVN) news for Monday includes positive interim results from clinical trials sending ARVN stock soaring to new highs. The post Arvinas News Alert: Why ARVN Stock Is Skyrocketing Today appeared ...

7 months ago - InvestorPlace

– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated patient...

7 months ago - GlobeNewsWire

– Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET –

7 months ago - GlobeNewsWire

NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announ...

8 months ago - GlobeNewsWire

– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial –

8 months ago - GlobeNewsWire

NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announ...

9 months ago - GlobeNewsWire

NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announ...

9 months ago - GlobeNewsWire

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...

10 months ago - GlobeNewsWire

NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...

11 months ago - GlobeNewsWire

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -12.07% and 0.40%, respectively, for the quarter ended June 2020.

11 months ago - Zacks Investment Research

NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today ...

11 months ago - GlobeNewsWire

Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...

1 year ago - GlobeNewsWire

NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...

1 year ago - GlobeNewsWire

NEW HAVEN, Conn., June 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno...

1 year ago - GlobeNewsWire

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response -

1 year ago - GlobeNewsWire

About ARVN

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastati... [Read more...]

Industry
Biotechnology
IPO Date
Sep 27, 2018
Stock Exchange
NASDAQ
Ticker Symbol
ARVN
Full Company Profile

Financial Performance

In 2020, Arvinas's revenue was $21.80 million, a decrease of -49.27% compared to the previous year's $42.98 million. Losses were -$119.33 million, 69.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for Arvinas stock is "Strong Buy." The 12-month stock price forecast is 113.85, which is an increase of 5.54% from the latest price.

Price Target
$113.85
(5.54% upside)
Analyst Consensus: Strong Buy